| Methods |
STUDY DESIGN: Parallel group single centre study, Spain outpatient allergy clinic. 5‐7 day run in / 6 week treatment period
RANDOMISATION: Randomised, no details
BLINDING double blind, placebo controlled, no details
WITHDRAWALS/DROP OUTS: 3 described.
COMPLIANCE: weighing used canisters, result 83% active group, 90% placebo.
CONFOUNDERS: participants not sensitized to other perennial allergens.
QUALITY: Jadad 3 Cochrane B |
| Participants |
N = 30 randomised, 27 completed. M= 7, F= 20 Mean age 39.5 yrs range 17‐55.
BASELINE SEVERITY: Seasonal mild asthma only.
INCLUSION : Clinical diagnosis seasonal asthma, Baseline FEV1 >80% predicted, positive skin prick test to pollen allergen and negative to perennial allergens.
EXCLUSION : Ever smoker, perennial asthma, COPD, URTI within 4 weeks, regular use of asthma therapy. |
| Interventions |
LONG ACTING BETA AGONIST: Salmeterol 50mcg BD
PLACEBO: BD
DEVICE: MDI via spacer
RESCUE: Albuterol via MDI
TREATMENT PERIOD: 6 weeks
CO‐INTERVENTIONS: none permitted |
| Outcomes |
OUTCOMES: BHR PC20 methacholine, PC20 AMP, exhaled nitric oxide level, FEV1 |
| Notes |
|
